MedCloud Minute
The MedCloud Minute blog is researched, fact-checked, edited and updated by the editors of MedCloudInsider.com, with writing assistance from AI. To submit your company's press release for consideration, contact [email protected].
Astrin Biosciences, a cancer intelligence company, has established a scientific advisory board to support the development of its AI-enabled proteomics platform for early cancer detection. The new board includes clinicians and researchers with backgrounds in oncology, biomarker discovery and machine learning, who will advise on study design, validation strategies and clinical translation. The development of the board comes post the launch of Astrin's Certitude Breast, a non-imaging screening test that can detect breast cancer in early stages. Astrin claims expert input is critical as it advances toward larger trials and potential regulatory pathways.
Interest in proteomic diagnostics has accelerated as researchers look beyond genomics for earlier and more accurate detection tools. For health systems seeking noninvasive screening options, platforms that leverage AI to interpret complex protein data could offer a complementary route to earlier detection and improved outcomes.
Posted by MedCloudInsider Editors on 12/08/20250 comments
Inductive Bio, an AI drug discovery partner, has received an award of up to $21 million to advance AI-driven toxicity models intended to improve drug safety assessment and reduce downstream development risk. The company will work with leading academic and biopharmaceutical partners to generate datasets, validate predictive models and evaluate how AI can better characterize off-target effects early in the R&D cycle. Inductive Bio aims to use the initiative to address persistent gaps in preclinical toxicity screening, where conventional models often fail to capture complex biological interactions that later lead to trial delays or program termination.
Safety-related attrition remains one of the most costly challenges in drug development. Inductive Bio’s effort, backed by a multi-institution consortium, reflects growing momentum toward shared datasets and collaborative validation frameworks. For biopharma R&D teams under pressure to cut costs and accelerate timelines, more accurate toxicity forecasting could materially reshape portfolio decision-making.
Posted by MedCloudInsider Editors on 12/08/20250 comments
ALR Technologies, a data management company, plans to relaunch its GluCurve Pet Continuous Glucose Monitor (CGM) in January 2026. The device is designed to help veterinarians and pet owners monitor glucose levels in diabetic cats and dogs through continuous, automated readings rather than periodic manual tests. Blood sugar readings are uploaded to the ALRT Veterinary Web Portal so that vets can easily monitor readings and adjust insulin levels accordingly for their patients.
The pet diabetes market has grown steadily as diagnosis rates rise and owners seek better tools to manage chronic conditions. A successful GluCurve relaunch could give clinics a more standardized tool for treatment adjustments, potentially reducing hypoglycemia risk and improving long-term outcomes for diabetic pets.
Posted by MedCloudInsider Editors on 12/08/20250 comments
CaliberMRI, an automation software and imaging phantoms company, has introduced the qDisc, a new quantitative MRI phantom designed to augment the functionality of the Medium ACR Phantom commonly used in clinical quality-assurance workflows. The qDisc provides stable reference materials for diffusion, T1/T2 relaxation and temperature measurements, allowing imaging teams to perform more comprehensive scanner performance checks without adding complex new equipment. The company says the device provides a practical option to gather metrics during routine scans. The harmonization of MRI scanners and AI software for analysis can be done using the qDisc, which complements CaliberMRI's existing offerings.
Interest in quantitative MRI is rising as hospitals and research centers adopt standardized metrics to compare imaging across scanners and sites. The qDisc’s integration with the ACR phantom offers a practical path for sites that want to expand quantitative QA without overhauling existing processes.
Posted by MedCloudInsider Editors on 12/01/20250 comments
Hoppr and Ferrum Health, an AI-insights service provider, have announced a partnership to launch a full foundation-model development suite designed specifically for healthcare organizations. The platform will allow hospitals, research centers and developers to build or fine-tune large medical AI models using their own imaging and clinical datasets while keeping all data within a secure, compliance-focused environment. The integrated suite offers development tooling, data curation, model training, evaluation frameworks, interoperability and seamless deployment into Ferrum's governance layer.
The initiative reflects growing interest in health-system–owned AI, where organizations want more control over model performance, data privacy and clinical integration. The Hoppr–Ferrum approach emphasizes end-to-end tooling tied directly to clinical governance. For health systems dealing with variable imaging protocols and diverse patient populations, localized model adaptation is increasingly viewed as essential for safe and reliable AI deployment.
Posted by MedCloudInsider Editors on 12/01/20250 comments
ScreenPoint Medical, an AI-powered technological company specializing in breast imaging to help detect breast cancer, showcased new advancements to its Transpara Breast AI Suite at RSNA 2025. The updated suite provides risk scoring, lesion detection and triage tools designed to help radiologists prioritize cases and identify cancers earlier, particularly in dense breast tissue. The company noted that Transpara is already in clinical use in more than 30 countries and is designed to integrate with existing PACS and reading workflows without major process changes.
Interest in breast imaging AI continues to grow as radiology groups face rising exam volumes and persistent staffing shortages. ScreenPoint’s long-standing focus on reader support and case triage positions Transpara as a mature option for clinics seeking incremental adoption rather than full workflow redesign. Another development included Transpara Risk that produces an image-based 5 year risk model for breast cancer along with Transpara Detection which is still being researched for investigational use only.
Posted by MedCloudInsider Editors on 12/01/20250 comments
Hoth Therapeutics, a clinical-stage biopharmaceutical company, has been accepted into the NVIDIA Connect Program, providing the company with access to NVIDIA’s accelerated computing and AI development resources. Hoth plans to use these tools to speed computational modeling, data processing, and target evaluation across its early-stage pipeline, which includes programs in dermatology, inflammation, and oncology. The company said the program will support both internal research and collaborations by enabling larger-scale simulations and AI-driven analysis. The connection provides Hoth Therapeutics with GPU-accelerated developer tools, SDKs and APIs as well as co-marketing for increased visibility.
The move reflects broader adoption of high-performance computing in biotech, where AI-assisted drug discovery is rapidly becoming standard. For smaller developers like Hoth, access to NVIDIA tooling through an accelerator program offers a cost-effective way to modernize computational workflows without building extensive in-house hardware capacity.
Posted by MedCloudInsider Editors on 11/24/20250 comments
Aperture Therapeutics, a preclinical biotechnology company, has announced a new development candidate targeting CD33, a receptor implicated in dysfunctional microglial activity in frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The therapy is designed to restore microglial homeostasis by modulating CD33 signaling, which research shows can reduce harmful inflammatory responses and improve debris clearance in the central nervous system. The company reports that preclinical work supports CD33 as a viable path toward slowing or modifying disease progression, and the candidate will advance into IND-enabling studies.
Interest in microglia-focused therapeutics has grown as genetic studies link innate immune dysregulation to neurodegeneration. Aperture’s CD33-specific approach adds a differentiated mechanism to the pipeline. The optimization of CD33 modulators was supported by the National Institute of Neurological Disorders and Stroke (NINDS/NIH).
Posted by MedCloudInsider Editors on 11/24/20250 comments
Citius Oncology plans to integrate Verix AI into the commercial launch of LYMPHIR, its recently approved IL-2 receptor–directed fusion protein for adults with persistent or recurrent cutaneous T-cell lymphoma (CTCL). Verix AI will support real-world patient identification, streamline specialty distribution workflows, and provide field teams with coordinated insights for clinician engagement. Citius says the platform is intended to improve speed-to-treatment in a rare cancer where diagnosis is often delayed and access pathways can be complex.
The move reflects a growing trend in oncology toward using AI to accelerate therapy adoption and improve care coordination. Verix’s focus on linking patient analytics with field operations provides a more integrated approach. For health systems, the combination of LYMPHIR and Verix AI could improve identification of eligible CTCL patients—a population often managed across dermatology and oncology clinics with inconsistent data visibility.
Posted by MedCloudInsider Editors on 11/24/20250 comments
Rapid Nexus, a medical device company, has become the first to receive FDA clearance for an advanced wound-healing gel device designed to support early-stage tissue recovery. The device, Hemastyl, uses a proprietary formulation and applicator system intended for use in emergency medicine, surgery and outpatient wound care. According to the company, Hemastyl can quickly stop bleeding while creating an environment that promotes faster healing and reduces complication risks—key needs in trauma and chronic wound settings.
The clearance arrives as demand grows for technologies that address rising rates of chronic wounds linked to diabetes, vascular diseases and aging populations. Hemastyl’s combined hemostatic and healing-support approach may appeal to emergency departments and ambulatory surgical centers seeking faster, more predictable outcomes.
Posted by MedCloudInsider Editors on 11/17/20250 comments
Lunit, an AI for cancer diagnostics provider and Labcorp, an innovative laboratory service provider, have announced a strategic collaboration to expand AI-powered digital pathology research, combining Labcorp’s large-scale tissue datasets with Lunit’s AI models for slide interpretation. The partnership will focus on improving biomarker discovery, refining diagnostic accuracy and supporting translational research in oncology. Lunit’s algorithms will be applied to Labcorp’s scanned pathology slides to analyze tumor microenvironments, quantify biomarkers and identify patterns that may guide treatment selection. The companies say the work will support both early-stage research and future clinical study design.
The move highlights increasing adoption of AI in histopathology, where digitization and high-throughput image analysis are now central to cancer research. Labcorp’s extensive specimen network may give the partnership a unique advantage in scale and diversity of training data. The collaboration aims to broaden cancer and genomic correlations through the application of AI and digital pathology.
Posted by MedCloudInsider Editors on 11/17/20250 comments
Leucid Bio, a biotechnology company dedicated to the development of cell therapies, has shared an update from its ongoing Phase I/IIa AERIAL clinical trial evaluating LEU011, a Lateral CAR-T therapy targeting NKG2D ligands in advanced solid tumors. Interim results show sustained partial responses and evidence of immune persistence in patients with recurrent or metastatic head and neck squamous cell carcinoma. The treatment demonstrated a manageable safety profile with no new dose-limiting toxicities.
The findings mark progress for CAR-T therapies in solid tumors, a field long constrained by tumor microenvironment challenges. Leucid’s “lateral” CAR architecture—designed to improve T-cell persistence and tumor penetration—could represent a breakthrough in solid tumor immunotherapy. Full Phase II results are expected in the first half 2026.
Posted by MedCloudInsider Editors on 11/10/20250 comments